COVID-19 Funding Opportunities
The Office of the Vice Provost for Research (VPR) has compiled a list of funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
Deadline: Monday, June 14, 2021 at 11:59 PM
BOOST and PROPEL awards are clinical research
grants that award Clinical
Research Unit (CRU) resources such as research space, specialized
research nursing, imaging assistance (i.e. DXA,CV core), and research
nutrition resources to ICTR investigators, based on merit and willingness
to be actively monitored by the Translational Research Evaluation Committee
(TREC) for study-specific milestones. All projects are monitored on
a quarterly basis for attainment of milestones.
The goal of these awards is designed to accelerate
meritorious protocols to produce efficient, high quality, safe and disseminatable
research. They are unique within the ICTR in that awards are for CRU
resources and applicants undergo a rigorous, NIH-style, multidisciplinary
review process via the TREC review committee.
BOOST- For junior investigators, first-time
R01 awardees, K awardees, and KL2 scholars to generate pilot data for
a larger grant submission or to supplement research funds for the K
PROPEL- For established investigators who
are performing early stage clinical trials, deep phenotyping studies,
or studies that address Maryland health priorities. Propel can augment
resources of a funded project or provide resources for small pilot and
All investigators must submit an application to
a Johns Hopkins Institutional Review Board (IRB) before beginning their
BOOST/PROPEL application. The CRU must be selected as a study site by
completing Section 9, questions and 10 on the eIRB application.
Applications must be submitted through the ICTR
Connection Request website:
Application Deadline: June
18, 2021, 11:59 pm
While many awards still go to individuals, advances
in translational research are increasingly dependent on teams of individuals
with different perspectives and skills working collaboratively towards
a common goal. The concept of Team Science answers the question, "How
do groups, particularly interdisciplinary groups, move through a process
together?" Although seemingly simple, the field that studies the
Science of Team Science has demonstrated that successfully conducting
science in teams can be anything but. Thus, the goal of this award is
to recognize the great work Johns Hopkins researchers have been doing
as interdisciplinary teams and to highlight best practices and share
lessons learned in Team Science. We expect this will be an annual award.
Three teams within the Johns Hopkins system will
be selected to receive the ICTR Team Science Award. In addition to self-satisfaction
and external validation, these three teams will:
Teams will be provided with a project-specific
consultation by the ICTR Navigators to help identify how the ICTR can
best support their research.
Any person within Johns Hopkins who is part of
a Team Science biomedical research project is eligible to submit an
application on behalf of a team. A Team Science project is defined as
any group of interdisciplinary researchers working collaboratively toward
a specific scientific goal. Interdisciplinary research can be defined
as either cross-school collaborations (i.e., Medicine, Public Health,
Nursing, Engineering, Arts & Sciences, Education, or Business),
or as collaborations across different multiple department or fields
of study. (See the National
Cancer Institute's Collaboration and Team Science Field Guide for more
information on Team Science.) The team must include at least three
members, led or co-led by a Johns Hopkins researcher, and have worked
together on more than one research protocol.
Applications must be submitted here: https://redcap.link/TeamScience
For more information, visit https://ictr.johnshopkins.edu/funding_opps/funding-opportunities/ictr-team-science-award/
or contact TeamScience@jhmi.edu
by June 4, 2021.
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.